Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASBP Aspire Biopharma	$0.55 +1.7%	$0.37	$0.22 ▼ $15.80	$26.60M	0.79	27.19 million shs	4.14 million shs
AYTU Aytu BioPharma	$2.20 +0.9%	$2.29	$0.95 ▼ $2.85	$19.57M	0.13	113,806 shs	93,694 shs
CMMB Chemomab Therapeutics	$0.89 +0.6%	$1.09	$0.87 ▼ $2.55	$16.78M	0.52	114,253 shs	302,411 shs
IPCIF Intellipharmaceutics International		$0.00	$0.00 ▼ $0.15	$4.96M	1.53	12,042 shs	N/A

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASBP Aspire Biopharma	+1.66%	+52.12%	+31.53%	+54,609,900.00%	+54,609,900.00%
AYTU Aytu BioPharma	+0.92%	-0.45%	-16.35%	+12.24%	-18.22%
CMMB Chemomab Therapeutics	+0.56%	-4.30%	-19.09%	-34.80%	-27.05%
IPCIF Intellipharmaceutics International	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	3.1359 of 5 stars	3.5	2.0	0.0	3.4	0.0	0.0	0.6
CMMB Chemomab Therapeutics	3.4984 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.6
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASBP Aspire Biopharma	0.00	N/A	N/A	N/A
AYTU Aytu BioPharma	3.00	Buy	$10.00	354.55% Upside
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	855.06% Upside
IPCIF Intellipharmaceutics International	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPCIF, AYTU, ASBP, and CMMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	($0.19) per share	N/A
AYTU Aytu BioPharma	$81M	0.24	N/A	N/A	$4.64 per share	0.47
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.51 per share	N/A
IPCIF Intellipharmaceutics International	$660K	0.00	N/A	N/A	($0.32) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASBP Aspire Biopharma	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	-737.96%	N/A
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-94.71%	-76.53%	N/A
IPCIF Intellipharmaceutics International	-$2.89M	-$0.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IPCIF, AYTU, ASBP, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/13/2025	Q2 2025	ASBP Aspire Biopharma	N/A	-$0.04	N/A	-$0.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASBP Aspire Biopharma	N/A	0.09	0.09
AYTU Aytu BioPharma	0.27	1.03	0.87
CMMB Chemomab Therapeutics	N/A	7.42	5.33
IPCIF Intellipharmaceutics International	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASBP Aspire Biopharma	19.17%
AYTU Aytu BioPharma	33.49%
CMMB Chemomab Therapeutics	46.05%
IPCIF Intellipharmaceutics International	N/A

Insider Ownership

Company	Insider Ownership
ASBP Aspire Biopharma	48.00%
AYTU Aytu BioPharma	3.60%
CMMB Chemomab Therapeutics	11.91%
IPCIF Intellipharmaceutics International	1.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASBP Aspire Biopharma	N/A	49.53 million	25.75 million	N/A
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
IPCIF Intellipharmaceutics International	10	33.09 million	32.51 million	Not Optionable

IPCIF, AYTU, ASBP, and CMMB Headlines

Recent News About These Companies

Intellipharmaceutics Announces Downgrade to OTC Expert Market

June 14, 2024 | accesswire.comA

Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan

March 13, 2024 | accesswire.comA

Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Cease Trade Order

March 6, 2024 | finanznachrichten.de

Intellipharmaceutics Announces Cease Trade Order

March 6, 2024 | accesswire.comA

Intellipharmaceutics International Inc. (IPCI.TO)

February 28, 2024 | ca.finance.yahoo.com

Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form

February 26, 2024 | accesswire.comA

Intellipharmaceutics International Inc. Announces Stock Option Grant

February 8, 2024 | finance.yahoo.com

Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange

January 2, 2024 | finance.yahoo.com

Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2023 Results

October 16, 2023 | finanznachrichten.de

Intellipharmaceutics Announces Second Quarter 2023 Results

July 14, 2023 | finance.yahoo.com

Closing Bell: Intellipharmaceutics International Inc up on Monday (IPCI)

June 27, 2023 | theglobeandmail.com

Closing Bell: Intellipharmaceutics International Inc up on Friday (IPCI)

June 10, 2023 | theglobeandmail.com

Intellipharmaceutics International reports FY 2022 and Q1 2023 results

June 6, 2023 | msn.com

Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results

June 6, 2023 | finance.yahoo.com

Jim Cramer -- International Paper, United Technologies Looking More Attractive

May 10, 2023 | thestreet.com

Closing Bell: Intellipharmaceutics International Inc flat on Tuesday (IPCI)

April 12, 2023 | theglobeandmail.com

Closing Bell: Intellipharmaceutics International Inc flat on Thursday (IPCI)

April 11, 2023 | theglobeandmail.com

IPCIF Intellipharmaceutics International Inc.

March 17, 2023 | seekingalpha.com

Intellipharmaceutics Announces Cease Trade Order

March 7, 2023 | finance.yahoo.com

Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form and its Management Cease Trade Order Application

February 6, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPCIF, AYTU, ASBP, and CMMB Company Descriptions

Aspire Biopharma NASDAQ:ASBP

$0.55 +0.01 (+1.66%)

As of 08/22/2025 04:00 PM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Aytu BioPharma NASDAQ:AYTU

$2.20 +0.02 (+0.92%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.19 -0.01 (-0.45%)

As of 08/22/2025 07:46 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Chemomab Therapeutics NASDAQ:CMMB

$0.89 +0.01 (+0.56%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$0.87 -0.02 (-2.25%)

As of 08/22/2025 07:59 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Intellipharmaceutics International OTCMKTS:IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time